A Study to Evaluate the Safety and Efficacy of IMMU-132 (Sacituzumab Govitecan) in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Progressed on Second Generation AR-Directed Therapy
Phase of Trial: Phase II
Latest Information Update: 22 Nov 2019
Price : $35 *
At a glance
- Drugs Sacituzumab govitecan (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 06 Nov 2018 Status changed from not yet recruiting to recruiting.
- 29 Oct 2018 Status changed from planning to not yet recruiting.
- 12 Jan 2018 New trial record